Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of novel T-cell therapies for the treatment of solid tumors. The company’s proprietary technology platform, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells, uses affinity-enhanced T-cell receptors (TCRs) to target cancer-associated antigens with precision. Adaptimmune’s research and development efforts are centered on engineering patient-derived T cells to recognize and eliminate tumor cells while sparing healthy tissues.
Since its founding in 2008 as a spin-out from Oxford University, Adaptimmune has advanced multiple product candidates into clinical trials. Lead programs include ADP-A2M4, targeting the cancer testis antigen MAGE-A4, and ADP-A2AFP, directed against alpha-fetoprotein in liver cancer. The company also maintains preclinical discovery efforts against other tumor-associated antigens, aiming to expand its pipeline across a range of solid tumor indications such as ovarian, head and neck, and lung cancers.
Adaptimmune operates research and development facilities in Oxford, U.K., and a clinical and manufacturing center in Philadelphia, Pennsylvania. The company conducts multicenter clinical trials primarily in the United States and Europe, collaborating with academic institutions and biopharmaceutical partners to facilitate patient access and advance its programs through late-stage development.
Governed by a management team with deep expertise in oncology and cell therapy, Adaptimmune is led by Chief Executive Officer James Noble, who joined the company in 2021. Adaptimmune Therapeutics is publicly traded on the Nasdaq Global Market under the ticker symbol ADAP and continues to pursue strategic collaborations and potential regulatory filings as it works to bring its engineered T-cell therapies to patients with unmet medical needs.
AI Generated. May Contain Errors.
